New cocktail of drugs takes on Hard-to-Treat prostate cancer
NCT ID NCT02861573
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to other cancer treatments can help men with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread and no longer responds to hormone therapy. About 1,200 participants will receive one of several combination therapies, including pembrolizumab with olaparib, docetaxel, enzalutamide, or lenvatinib. The goal is to see if these combinations are safe and can shrink tumors or lower PSA levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) combined with other drugs like olaparib, docetaxel, enzalutamide, or lenvatinib
What this could lead to
If successful, this could offer new combination treatment options for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early-phase trial (Phase 1/2) with many different drug combinations, so results are preliminary. Side effects from combining these powerful drugs could be significant, and not all combinations may prove effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Call for Information (Investigational Site 0016)
Seattle, Washington, 98109, United States
-
Call for Information (Investigational Site 0019)
Myrtle Beach, South Carolina, 29572, United States
-
Call for Information (Investigational Site 2041)
Aurora, Colorado, 80045, United States
-
Call for Information (Investigational Site 2090)
Germantown, Tennessee, 38138, United States
-
Call for Information (Investigational Site 2091)
Cleveland, Ohio, 44195, United States
-
Call for Information (Investigational Site 2094)
Portland, Oregon, 97239, United States
-
MSD Comercializadora, S. de R.L. de C.V.
Mexico City, Mexico
-
MSD Denmark
Glostrup Municipality, Denmark
-
MSD France
Paris, France
-
MSD Ireland (Human Health) Ltd.
Dublin, Ireland
-
MSD Polska Sp. Z o.o.
Warsaw, Poland
-
MSD Sweden
Stockholm, Sweden
-
Merck Sharp & Dohme BV
Haarlem, Netherlands
-
Merck Sharp & Dohme Ltd.
London, United Kingdom